{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:29:13Z","timestamp":1760315353662,"version":"build-2065373602"},"reference-count":182,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Signalling"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.cellsig.2022.110559","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T20:21:32Z","timestamp":1670876492000},"page":"110559","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["COVID-19 signalome: Potential therapeutic interventions"],"prefix":"10.1016","volume":"103","author":[{"given":"Kenneth","family":"Lundstrom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Altijana","family":"Hromi\u0107-Jahjefendi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esma","family":"Bilajac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alaa A.A.","family":"Aljabali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarina","family":"Barali\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagwa A.","family":"Sabri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eslam M.","family":"Shehata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Raslan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara A.","family":"Raslan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Cl\u00e1udia B.H.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidiane","family":"Orlandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngel","family":"Serrano-Aroca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir N.","family":"Uversky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sk. Sarif","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elrashdy M.","family":"Redwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasco","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid J.","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalaf F.","family":"Alsharif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim F.","family":"Halawani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuad M.","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murtaza M.","family":"Tambuwala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debmalya","family":"Barh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellsig.2022.110559_bb0010","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.3390\/v13102098","article-title":"COVID-19 in 2021","volume":"13","author":"Lundstrom","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.cellsig.2022.110559_bb0015","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1042\/CS20200904","article-title":"Unpuzzling COVID-19: tissue-related Signaling pathways associated with SARS-CoV-2 infection and transmission","volume":"134","author":"Battagello","year":"2020","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.cellsig.2022.110559_bb0020","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0014-5793(02)03640-2","article-title":"Quantitative MRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme","volume":"532","author":"Harmer","year":"2002","journal-title":"FEBS Lett."},{"key":"10.1016\/j.cellsig.2022.110559_bb0025","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/path.1570","article-title":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis","volume":"203","author":"Hamming","year":"2004","journal-title":"J. Pathol."},{"key":"10.1016\/j.cellsig.2022.110559_bb0030","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus\u2013induced lung injury","volume":"11","author":"Kuba","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.cellsig.2022.110559_bb0035","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","article-title":"Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target","volume":"46","author":"Zhang","year":"2020","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.cellsig.2022.110559_bb0040","doi-asserted-by":"crossref","unstructured":"Cao, Z.; Wu, Y.; Faucon, E.; Sabatier, J.-M. SARS-CoV-2 & Covid-19: key-roles of the \u2018Renin-Angiotensin\u2019 system\/Vitamin D impacting drug and vaccine developments. Infect. Disorders - Drug Targets 20, 348\u2013349.","DOI":"10.2174\/1871526520999200505174704"},{"key":"10.1016\/j.cellsig.2022.110559_bb0045","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1007\/s11427-014-4693-3","article-title":"ACE2\/Ang-(1\u20137) Signaling and Vascular Remodeling","volume":"57","author":"Zhang","year":"2014","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.cellsig.2022.110559_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102537","article-title":"The role of cytokines including Interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease","volume":"19","author":"McGonagle","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.cellsig.2022.110559_bb0055","first-page":"607","article-title":"The pathogenesis and treatment of the `cytokine storm\u2019 in COVID-19","volume":"80","author":"Ye","year":"2020","journal-title":"J. Inf. Secur."},{"key":"10.1016\/j.cellsig.2022.110559_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30216-2","article-title":"COVID-19 cytokine storm: the interplay between inflammation and coagulation","author":"Jose","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.cellsig.2022.110559_bb0065","article-title":"SARS-CoV-2 triggers golgi fragmentation via down-regulation of GRASP55 to facilitate viral trafficking","author":"Zhang","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.cellsig.2022.110559_bb0070","doi-asserted-by":"crossref","unstructured":"Ghasemnejad-Berenji, M.; Pashapour, S. SARS-CoV-2 and the possible role of Raf\/MEK\/ERK pathway in viral survival: is this a potential therapeutic strategy for COVID-19? Pharmacology 1, doi:https:\/\/doi.org\/10.1159\/000511280.","DOI":"10.1159\/000511280"},{"key":"10.1016\/j.cellsig.2022.110559_bb0075","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1158\/2159-8290.CD-20-0559","article-title":"The landscape of human cancer proteins targeted by SARS-CoV-2","volume":"10","author":"Tutuncuoglu","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cellsig.2022.110559_bb0080","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","article-title":"A SARS-CoV-2 protein interaction map reveals targets for drug repurposing","volume":"583","author":"Gordon","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cellsig.2022.110559_bb0085","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1136\/jclinpath-2020-206658","article-title":"Gene of the month: the 2019-NCoV\/SARS-CoV-2 novel coronavirus spike protein","volume":"73","author":"Pillay","year":"2020","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.cellsig.2022.110559_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104859","article-title":"Candidate drugs against SARS-CoV-2 and COVID-19","volume":"157","author":"McKee","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.cellsig.2022.110559_bb0095","article-title":"RNA-dependent RNA polymerase of SARS-CoV-2 as a therapeutic target","volume":"93","author":"Wang","year":"2021","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.cellsig.2022.110559_bb0100","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/viro.2001.1039","article-title":"Novo initiation of viral RNA-dependent RNA synthesis","volume":"287","author":"Kao","year":"2001","journal-title":"Virology"},{"key":"10.1016\/j.cellsig.2022.110559_bb0105","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.sbi.2005.12.002","article-title":"A comparison of viral RNA-dependent RNA polymerases","volume":"16","author":"Ferrer-Orta","year":"2006","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.cellsig.2022.110559_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117592","article-title":"Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study","volume":"253","author":"Elfiky","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.cellsig.2022.110559_bb0115","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in Rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.cellsig.2022.110559_bb0120","doi-asserted-by":"crossref","first-page":"eaal3653","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-Spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cellsig.2022.110559_bb0125","first-page":"117","article-title":"Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection","author":"De Wit","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cellsig.2022.110559_bb0130","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1099\/jgv.0.001453","article-title":"SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology","volume":"101","author":"Ogando","year":"2020","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.cellsig.2022.110559_bb0135","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-020-2423-5","article-title":"Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2","volume":"585","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cellsig.2022.110559_bb0140","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00162-20","article-title":"Remdesivir against COVID-19 and other viral diseases","volume":"34","author":"Malin","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.cellsig.2022.110559_bb0145","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 \u2014 final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellsig.2022.110559_bb0150","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1056\/NEJMp2032369","article-title":"FDA approval of Remdesivir \u2014 a step in the right direction","volume":"383","author":"Rubin","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellsig.2022.110559_bb0155","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.antiviral.2018.03.003","article-title":"Favipiravir as a potential countermeasure against neglected and emerging RNA viruses","volume":"153","author":"Delang","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.cellsig.2022.110559_bb0160","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2217\/fvl.13.98","article-title":"Synergistic combinations of favipiravir and oseltamivir against wild-type pandemic and oseltamivir-resistant Influenza A virus infections in mice","volume":"8","author":"Smee","year":"2013","journal-title":"Futur. Virol."},{"key":"10.1016\/j.cellsig.2022.110559_bb0165","first-page":"1192","article-title":"Experimental treatment with Favipiravir for COVID-19: an open-label control study","volume":"6","author":"Cai","year":"2020","journal-title":"Engineering (Beijing)"},{"key":"10.1016\/j.cellsig.2022.110559_bb0170","unstructured":"C. Chen, Y. Zhang, J. Huang, P. Yin, Z. Cheng, J. Wu, S. Chen, Y. Zhang, B. Chen, M. Lu, et al., Favipiravir versus arbidol for COVID-19: a randomized clinical trial, medRxiv (2020) (2020.03.17.20037432). This is pre-print referene and hence does not have any other details."},{"key":"10.1016\/j.cellsig.2022.110559_bb0175","article-title":"Real-world experience with favipiravir for treatment of COVID-19 in Thailand: results from a multicenter observational study","author":"Rattanaumpawan","year":"2020","journal-title":"MedRxiv"},{"key":"10.1016\/j.cellsig.2022.110559_bb0180","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01897-20","article-title":"A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19","volume":"64","author":"Doi","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.cellsig.2022.110559_bb0190","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1139\/cjpp-2020-0734","article-title":"Ribavirin shows antiviral activity against SARS-CoV-2 and downregulates the activity of TMPRSS2 and the expression of ACE2 in vitro","volume":"99","author":"Unal","year":"2021","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.cellsig.2022.110559_bb0195","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of Interferon Beta-1b, Lopinavir\u2013Ritonavir, and Ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, Phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cellsig.2022.110559_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106114","article-title":"Ribavirin therapy for severe COVID-19: a retrospective cohort study","volume":"56","author":"Tong","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.cellsig.2022.110559_bb0205","article-title":"Sofosbuvir\/Daclatasvir in the treatment of COVID-19 infection: a Meta-analysis","volume":"82","author":"Chan","year":"2021","journal-title":"J. Inf. Secur."},{"key":"10.1016\/j.cellsig.2022.110559_bb0210","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1093\/jac\/dkaa331","article-title":"The impact of Sofosbuvir\/Daclatasvir or ribavirin in patients with severe COVID-19","volume":"75","author":"Eslami","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.cellsig.2022.110559_bb0215","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1093\/jac\/dkaa334","article-title":"Sofosbuvir and Daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial","volume":"75","author":"Sadeghi","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.cellsig.2022.110559_bb0220","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1093\/jac\/dkaa332","article-title":"Evaluation of the efficacy of Sofosbuvir plus Daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial","volume":"75","author":"Abbaspour Kasgari","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.cellsig.2022.110559_bb0230","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41564-020-00835-2","article-title":"Therapeutically administered Ribonucleoside analogue MK-4482\/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets","volume":"6","author":"Cox","year":"2021","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.cellsig.2022.110559_bb0235","doi-asserted-by":"crossref","first-page":"eabb5883","DOI":"10.1126\/scitranslmed.abb5883","article-title":"An orally bioavailable broad-Spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice","volume":"12","author":"Sheahan","year":"2020","journal-title":"Sci. Transl. Med."},{"author":"Ridgeback Biotherapeutics","key":"10.1016\/j.cellsig.2022.110559_bb0240"},{"year":"2020","series-title":"The Safety of Molnupiravir (EIDD-2801) and its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)","author":"Ridgeback Biotherapeutics","key":"10.1016\/j.cellsig.2022.110559_bb0245"},{"key":"10.1016\/j.cellsig.2022.110559_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2021.102329","article-title":"Molnupiravir in COVID-19: a systematic review of literature","volume":"15","author":"Singh","year":"2021","journal-title":"Diabetes Metab. Syndr."},{"key":"10.1016\/j.cellsig.2022.110559_bb0260","article-title":"Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses in cell culture","author":"Hu","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.cellsig.2022.110559_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.cellsig.2022.110559_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100720","article-title":"The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial","volume":"32","author":"Chaccour","year":"2021","journal-title":"eClinicalMedicine"},{"year":"2021","series-title":"Outcomes of Ivermectin in the Treatment of COVID-19: A Systematic Review and Meta-Analysis","author":"Casta\u00f1eda-Sabogal","key":"10.1016\/j.cellsig.2022.110559_bb0275"},{"key":"10.1016\/j.cellsig.2022.110559_bb0280","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1056\/NEJMoa2115869","article-title":"Effect of early treatment with Ivermectin among patients with Covid-19","volume":"386","author":"Reis","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellsig.2022.110559_bb0285","article-title":"Covid-19: Pfizer\u2019s Paxlovid is 89% effective in patients at risk of serious illness, company reports","volume":"375","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.cellsig.2022.110559_bb0290","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1021\/acsinfecdis.0c00168","article-title":"Characterization and noncovalent inhibition of the Deubiquitinase and DeISGylase activity of SARS-CoV-2 papain-like protease","volume":"6","author":"Freitas","year":"2020","journal-title":"ACS Infect Dis."},{"key":"10.1016\/j.cellsig.2022.110559_bb0295","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","article-title":"Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity","volume":"587","author":"Shin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cellsig.2022.110559_bb0300","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1016\/j.bmcl.2009.07.009","article-title":"Investigation of the pharmacophore space of severe acute respiratory syndrome coronavirus (SARS-CoV) NTPase\/helicase by dihydroxychromone derivatives","volume":"19","author":"Lee","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.cellsig.2022.110559_bb0305","doi-asserted-by":"crossref","DOI":"10.1007\/s12272-012-0108-9","article-title":"Synthesis and antiviral evaluation of 7-O-Arylmethylquercetin derivatives against SARS-associated coronavirus (SCV) and hepatitis C virus (HCV)","volume":"35","author":"Park","year":"2012","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.cellsig.2022.110559_bb0310","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1016\/j.bmcl.2012.04.081","article-title":"Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, NsP13","volume":"22","author":"Yu","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.cellsig.2022.110559_bb0315","first-page":"150","article-title":"Molecular mechanisms of Galidesivir as a potential antiviral treatment for COVID-19","author":"Ataei","year":"2020","journal-title":"J. Pharm. Care"},{"key":"10.1016\/j.cellsig.2022.110559_bb0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42003-020-01577-x","article-title":"Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents","volume":"4","author":"Mody","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.cellsig.2022.110559_bb0325","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1208\/s12248-007-9000-9","article-title":"The pharmacokinetics and interactions of Ivermectin in humans\u2014a Mini-review","volume":"10","author":"Canga","year":"2008","journal-title":"AAPS J."},{"key":"10.1016\/j.cellsig.2022.110559_bb0330","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.arbr.2020.06.006","article-title":"Antiviral and anti-inflammatory properties of Ivermectin and its potential use in COVID-19","volume":"56","author":"Portmann-Baracco","year":"2020","journal-title":"Arch. Bronconeumol. (Engl. Ed.)"},{"key":"10.1016\/j.cellsig.2022.110559_bb0335","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020106275","article-title":"Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2","volume":"39","author":"Klemm","year":"2020","journal-title":"EMBO J."},{"key":"10.1016\/j.cellsig.2022.110559_bb0340","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.9965","article-title":"Potential COVID-19 papain-like protease PLpro inhibitors: repurposing FDA-approved drugs","volume":"8","author":"Kouznetsova","year":"2020","journal-title":"PeerJ"},{"key":"10.1016\/j.cellsig.2022.110559_bb0345","doi-asserted-by":"crossref","first-page":"9144","DOI":"10.1021\/acs.jpclett.0c02421","article-title":"Discovery of COVID-19 inhibitors targeting the SARS-CoV-2 Nsp13 helicase","volume":"11","author":"White","year":"2020","journal-title":"J. Phys. Chem. Lett."},{"key":"10.1016\/j.cellsig.2022.110559_bb0350","first-page":"493","article-title":"Antiviral activity of cepharanthine against severe acute respiratory syndrome coronavirus in vitro","volume":"118","author":"Zhang","year":"2005","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.cellsig.2022.110559_bb0355","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.chembiol.2005.01.006","article-title":"The adamantane-derived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus","volume":"12","author":"Tanner","year":"2005","journal-title":"Chem. Biol."},{"key":"10.1016\/j.cellsig.2022.110559_bb0360","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.3390\/molecules25112707","article-title":"Potential of flavonoid-inspired phytomedicines against COVID-19","volume":"25","author":"Ngwa","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.cellsig.2022.110559_bb0365","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.3390\/nu5093367","article-title":"Flavonoid bioavailability and attempts for bioavailability enhancement","volume":"5","author":"Thilakarathna","year":"2013","journal-title":"Nutrients"},{"key":"10.1016\/j.cellsig.2022.110559_bb0370","doi-asserted-by":"crossref","first-page":"7744","DOI":"10.1073\/pnas.1817251116","article-title":"Photothermal-responsive nanosized hybrid polymersome as versatile therapeutics codelivery nanovehicle for effective tumor suppression","volume":"116","author":"Zhang","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.cellsig.2022.110559_bb0375","doi-asserted-by":"crossref","first-page":"7448","DOI":"10.7150\/thno.48076","article-title":"SARS-CoV-2 pandemic and research gaps: understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy","volume":"10","author":"Datta","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.cellsig.2022.110559_bb0380","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","article-title":"Structural basis of receptor recognition by SARS-CoV-2","volume":"581","author":"Shang","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cellsig.2022.110559_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.imu.2020.100407","article-title":"Predicted therapeutic targets for COVID-19 disease by inhibiting SARS-CoV-2 and its related receptors","volume":"20","author":"Balmeh","year":"2020","journal-title":"Inform. Med. Unlock."},{"key":"10.1016\/j.cellsig.2022.110559_bb0390","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.cellsig.2022.110559_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.109957","article-title":"Is hesperidin essential for prophylaxis and treatment of COVID-19 infection?","volume":"144","author":"Haggag","year":"2020","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.cellsig.2022.110559_bb0400","doi-asserted-by":"crossref","first-page":"742","DOI":"10.3390\/antiox9080742","article-title":"Hesperidin and SARS-CoV-2: new light on the healthy function of citrus fruits","volume":"9","author":"Bellavite","year":"2020","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.cellsig.2022.110559_bb0405","first-page":"9","article-title":"Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody","author":"Tian","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.cellsig.2022.110559_bb0410","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1038\/s41467-020-16256-y","article-title":"A human monoclonal antibody blocking SARS-CoV-2 infection","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cellsig.2022.110559_bb0415","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","volume":"583","author":"Pinto","year":"2020","journal-title":"Nature"},{"author":"Vir Biotechnology, Inc","key":"10.1016\/j.cellsig.2022.110559_bb0420"},{"key":"10.1016\/j.cellsig.2022.110559_bb0425","doi-asserted-by":"crossref","first-page":"1854149","DOI":"10.1080\/19420862.2020.1854149","article-title":"Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline","volume":"12","author":"Tuccori","year":"2020","journal-title":"MAbs"},{"author":"Eli Lilly and Company","key":"10.1016\/j.cellsig.2022.110559_bb0430"},{"key":"10.1016\/j.cellsig.2022.110559_bb0435","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19","volume":"384","author":"Chen","year":"2021","journal-title":"N. Engl. J. Med."},{"year":"2006","series-title":"Drugs and Lactation Database (LactMed)","author":"Etesevimab","key":"10.1016\/j.cellsig.2022.110559_bb0440"},{"key":"10.1016\/j.cellsig.2022.110559_bb0445","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1001\/jama.2021.0202","article-title":"Effect of Bamlanivimab as monotherapy or in combination with Etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial","volume":"325","author":"Gottlieb","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.cellsig.2022.110559_bb0460","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.abd0827","article-title":"Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail","volume":"369","author":"Hansen","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cellsig.2022.110559_bb0465","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1126\/science.abe2402","article-title":"REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters","volume":"370","author":"Baum","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cellsig.2022.110559_bb0470","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellsig.2022.110559_bb0475","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1056\/NEJMoa2109682","article-title":"Subcutaneous REGEN-COV antibody combination to prevent Covid-19","volume":"385","author":"O\u2019Brien","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellsig.2022.110559_bb0480","unstructured":"FDA Accepts REGEN-COV\u00ae (Casirivimab and Imdevimab) for Priority Review for Treatment and Prophylaxis of COVID-19, Regeneron Pharmaceuticals Inc. Available online: https:\/\/newsroom.regeneron.com\/news-releases\/news-release-details\/fda-accepts-regen-covr-casirivimab-and-imdevimab-priority-review\/ (accessed on 9 June 2022)."},{"key":"10.1016\/j.cellsig.2022.110559_bb0485","first-page":"2","article-title":"The current status of COVID-19 vaccines","author":"Lundstrom","year":"2020","journal-title":"Front. Genome Ed."},{"key":"10.1016\/j.cellsig.2022.110559_bb0490","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3390\/v13020317","article-title":"Viral vectors for COVID-19 vaccine development","volume":"13","author":"Lundstrom","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.cellsig.2022.110559_bb0495","doi-asserted-by":"crossref","first-page":"7892","DOI":"10.1016\/j.vaccine.2020.10.064","article-title":"NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge","volume":"38","author":"Guebre-Xabier","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.cellsig.2022.110559_bb0500","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa2116185","article-title":"Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico","volume":"386","author":"Dunkle","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellsig.2022.110559_bb0505","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.936523","article-title":"Editorial: first approval of the protein-based Adjuvanted Nuvaxovid (NVX-CoV2373) Novavax vaccine for SARS-CoV-2 could increase vaccine uptake and provide immune protection from viral variants","volume":"28","author":"Parums","year":"2022","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.cellsig.2022.110559_bb0510","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-18077-5","article-title":"An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques","volume":"11","author":"Feng","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cellsig.2022.110559_bb0515","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus Type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"year":"2021","series-title":"China Approves Two More Domestic COVID-19 Vaccines for Public Use","key":"10.1016\/j.cellsig.2022.110559_bb0520"},{"key":"10.1016\/j.cellsig.2022.110559_bb0525","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cell.2020.08.026","article-title":"A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2","volume":"183","author":"Hassan","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.cellsig.2022.110559_bb0530","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 NCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"year":"2020","series-title":"Russia Reports Positive Early Data on Covid-19 Vaccine Sputnik V","key":"10.1016\/j.cellsig.2022.110559_bb0540"},{"key":"10.1016\/j.cellsig.2022.110559_bb0545","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an RAd26 and RAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cellsig.2022.110559_bb0550","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an RAd26 and RAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cellsig.2022.110559_bb0555","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/d41586-020-02386-2","article-title":"Russia\u2019s fast-track coronavirus vaccine draws outrage over safety","volume":"584","author":"Callaway","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cellsig.2022.110559_bb0560","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-020-2607-z","article-title":"Single-shot Ad26 vaccine protects against SARS-CoV-2 in Rhesus macaques","volume":"586","author":"Mercado","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cellsig.2022.110559_bb0565","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a phase 1\u20132a trial of Ad26.COV2.S Covid-19 vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellsig.2022.110559_bb0575","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1126\/science.abc6284","article-title":"DNA vaccine protection against SARS-CoV-2 in Rhesus macaques","volume":"369","author":"Yu","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.cellsig.2022.110559_bb0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100689","article-title":"Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of an open-label, phase 1 clinical trial","volume":"31","author":"Tebas","year":"2021","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.cellsig.2022.110559_bb0585","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1093\/infdis\/jiac016","article-title":"SARS-CoV-2 DNA vaccine INO-4800 induces durable immune responses capable of being boosted in a phase 1 open-label trial","volume":"225","author":"Kraynyak","year":"2022","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.cellsig.2022.110559_bb0590","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cellsig.2022.110559_bb0595","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates","volume":"383","author":"Corbett","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellsig.2022.110559_bb0600","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 \u2014 preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellsig.2022.110559_bb0605","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1\u20132 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellsig.2022.110559_bb0610","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellsig.2022.110559_bb0620","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","article-title":"BNT162b vaccines protect rhesus macaques from SARS-CoV-2","volume":"592","author":"Vogel","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.cellsig.2022.110559_bb0625","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellsig.2022.110559_bb0630","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cellsig.2022.110559_bb0635","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"year":"2022","series-title":"Of the Comirnaty and Pfizer-BioNTech COVID-19 Vaccine","author":"Commissioner","key":"10.1016\/j.cellsig.2022.110559_bb0640"},{"key":"10.1016\/j.cellsig.2022.110559_bb0645","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1110\/ps.062730007","article-title":"Conductance and amantadine binding of a pore formed by a lysine-flanked transmembrane domain of SARS coronavirus envelope protein","volume":"16","author":"Torres","year":"2007","journal-title":"Protein Sci."},{"key":"10.1016\/j.cellsig.2022.110559_bb0650","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.bbrc.2020.05.206","article-title":"SARS-CoV-2 E protein is a potential ion channel that can be inhibited by gliclazide and memantine","volume":"530","author":"Singh Tomar","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cellsig.2022.110559_bb0655","doi-asserted-by":"crossref","first-page":"E254","DOI":"10.3390\/v12030254","article-title":"Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies","volume":"12","author":"Ahmed","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.cellsig.2022.110559_bb0660","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1021\/jm500089r","article-title":"Structural basis for the identification of the N-terminal domain of coronavirus nucleocapsid protein as an antiviral target","volume":"57","author":"Lin","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cellsig.2022.110559_bb0665","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1021\/acs.jmedchem.9b01913","article-title":"Structure-based stabilization of non-native protein-protein interactions of coronavirus Nucleocapsid proteins in antiviral drug design","volume":"63","author":"Lin","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cellsig.2022.110559_bb0670","article-title":"Current strategies of antiviral drug discovery for COVID-19","volume":"8","author":"Mei","year":"2021","journal-title":"Front. Mol. Biol."},{"key":"10.1016\/j.cellsig.2022.110559_bb0675","doi-asserted-by":"crossref","first-page":"295","DOI":"10.37349\/ei.2021.00020","article-title":"Viral vector-based vaccines against SARS-CoV-2","volume":"1","author":"Lundstrom","year":"2021","journal-title":"Explor. Immunol."},{"key":"10.1016\/j.cellsig.2022.110559_bb0680","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.virol.2004.09.033","article-title":"SARS coronavirus E protein forms cation-selective ion channels","volume":"330","author":"Wilson","year":"2004","journal-title":"Virology"},{"key":"10.1016\/j.cellsig.2022.110559_bb0685","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.virol.2006.05.028","article-title":"Hexamethylene amiloride blocks E protein ion channels and inhibits coronavirus replication","volume":"353","author":"Wilson","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.cellsig.2022.110559_bb0690","article-title":"Amantadine as a drug to mitigate the effects of COVID-19","volume":"140","author":"Abreu","year":"2020","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.cellsig.2022.110559_bb0695","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2020.198074","article-title":"The ORF6, ORF8 and Nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway","volume":"286","author":"Li","year":"2020","journal-title":"Virus Res."},{"key":"10.1016\/j.cellsig.2022.110559_bb0700","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020105938","article-title":"Structures of the SARS-CoV-2 nucleocapsid and their perspectives for drug design","volume":"39","author":"Peng","year":"2020","journal-title":"EMBO J."},{"key":"10.1016\/j.cellsig.2022.110559_bb0705","doi-asserted-by":"crossref","first-page":"342","DOI":"10.20411\/pai.v5i1.377","article-title":"The structure of the membrane protein of SARS-CoV-2 resembles the sugar transporter SemiSWEET","volume":"5","author":"Thomas","year":"2020","journal-title":"Pathog. Immun."},{"key":"10.1016\/j.cellsig.2022.110559_bb0710","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.RA120.016175","article-title":"The SARS-CoV-2 envelope and memrane proteins modulate maturation and retention of the spike protein, allowing assembly of virus-like particles","volume":"296","author":"Boson","year":"2021","journal-title":"Biol. Chem."},{"key":"10.1016\/j.cellsig.2022.110559_bb0715","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1042\/CS20150350","article-title":"Renin-angiotensin system as a potential therapeutic target in stroke and retinopathy: experimental and clinical evidence","volume":"130","author":"Fouda","year":"2016","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.cellsig.2022.110559_bb0720","doi-asserted-by":"crossref","unstructured":"van de Veerdonk, F.L.; Netea, M.G.; van Deuren, M.; van der Meer, J.W.; de Mast, Q.; Br\u00fcggemann, R.J.; van der Hoeven, H. Kallikrein-Kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. eLife 9, e57555, doi:https:\/\/doi.org\/10.7554\/eLife.57555.","DOI":"10.7554\/eLife.57555"},{"key":"10.1016\/j.cellsig.2022.110559_bb0725","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1152\/physrev.00038.2017","article-title":"Angiotensin II signal transduction: an update on mechanisms of physiology and pathophysiology","volume":"98","author":"Forrester","year":"2018","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.cellsig.2022.110559_bb0730","article-title":"Covid-19: risk factors for severe disease and death","volume":"368","author":"Jordan","year":"2020","journal-title":"BMJ (Clin. Res. ed.)"},{"key":"10.1016\/j.cellsig.2022.110559_bb0735","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/sj.jhh.1002101","article-title":"Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade","volume":"21","author":"Dandona","year":"2007","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.cellsig.2022.110559_bb0740","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1093\/eurheartj\/ehaa235","article-title":"SARS-CoV2: should inhibitors of the renin\u2013angiotensin system be withdrawn in patients with COVID-19?","volume":"41","author":"Kuster","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.cellsig.2022.110559_bb0745","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","article-title":"Association of Inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19","volume":"126","author":"Zhang","year":"2020","journal-title":"Circ. Res."},{"key":"10.1016\/j.cellsig.2022.110559_bb0750","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.7861\/clinmed.2020-0146","article-title":"The renin-angiotensin system - a therapeutic target in COVID-19?","volume":"20","author":"Sturrock","year":"2020","journal-title":"Clin. Med. (Lond.)"},{"key":"10.1016\/j.cellsig.2022.110559_bb0755","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1164\/rccm.202001-0179LE","article-title":"Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2","volume":"202","author":"Zhao","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cellsig.2022.110559_bb0760","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature03712","article-title":"Angiotensin-converting enzyme 2 protects from severe acute lung failure","volume":"436","author":"Imai","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.cellsig.2022.110559_bb0765","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s13054-017-1882-z","article-title":"Recombinant human ACE2: acing out angiotensin II in ARDS therapy","volume":"21","author":"Zhang","year":"2017","journal-title":"Crit. Care"},{"key":"10.1016\/j.cellsig.2022.110559_bb0770","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"19","key":"10.1016\/j.cellsig.2022.110559_bb0775","doi-asserted-by":"crossref","first-page":"e00683","DOI":"10.1128\/JVI.00683-18","article-title":"Middle East respiratory syndrome coronavirus spike protein is not activated directly by cellular Furin during viral entry into target cells","volume":"92","author":"Matsuyama","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.cellsig.2022.110559_bb0780","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.1128\/JVI.00094-12","article-title":"Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry","volume":"86","author":"Kawase","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.cellsig.2022.110559_bb0785","doi-asserted-by":"crossref","first-page":"6150","DOI":"10.1128\/JVI.03372-12","article-title":"TMPRSS2 activates the human coronavirus 229E for cathepsin-independent host cell entry and is expressed in viral target cells in the respiratory epithelium","volume":"87","author":"Bertram","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.cellsig.2022.110559_bb0790","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1124\/mol.110.064261","article-title":"A small-molecule oxocarbazate inhibitor of human cathepsin L blocks severe acute respiratory syndrome and ebola pseudotype virus infection into human embryonic kidney 293T cells","volume":"78","author":"Shah","year":"2010","journal-title":"Mol. Pharmacol."},{"issue":"87","key":"10.1016\/j.cellsig.2022.110559_bb0795","doi-asserted-by":"crossref","first-page":"8017","DOI":"10.1128\/JVI.00998-13","article-title":"Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms","volume":"2013","author":"Adedeji","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.cellsig.2022.110559_bb0800","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41392-020-0191-1","article-title":"Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2","volume":"5","author":"Catanzaro","year":"2020","journal-title":"Sig. Transduct. Target Ther."},{"key":"10.1016\/j.cellsig.2022.110559_bb0805","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4049\/jimmunol.2000513","article-title":"Inflammasomes and Pyroptosis as therapeutic targets for COVID-19","volume":"205","author":"Yap","year":"2020","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellsig.2022.110559_bb0810","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/s41591-021-01499-z","article-title":"Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomi zed controlled phase 3 trial","volume":"27","author":"Kyriazopoulou","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.cellsig.2022.110559_bb0815","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa2103417","article-title":"Therapeutic anticoagulation therapy with heparin in critically ill patients with COVID-19","volume":"385","author":"Goligher","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellsig.2022.110559_bb0820","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa2105911","article-title":"Therapeutic anticoagulation therapy with heparin in noncritically ill patients with COVID-19","volume":"385","author":"Lawler","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellsig.2022.110559_bb0825","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijbiomac.2020.06.228","article-title":"Targeting hub genes and pathways of innate immune response in COVID-19: a network biology perspective","volume":"163","author":"Prasad","year":"2020","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.cellsig.2022.110559_bb0830","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2021.101004","article-title":"Dysregulation of host cell calcium Signaling during viral infections: emerging paradigm with high clinical relevance","volume":"81","author":"Saurav","year":"2021","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.cellsig.2022.110559_bb0835","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3390\/cells10010030","article-title":"The PIKFyve inhibitor Apilimod: a double-edged sword against COVID-19","volume":"10","author":"Baranov","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.cellsig.2022.110559_bb0840","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.653","article-title":"Pharmacological hypothesis: TPC2 antagonist tetrandrine as a potential therapeutic agent for COVID-19","volume":"8","author":"Heister","year":"2020","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.cellsig.2022.110559_bb0845","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.3390\/cells10051130","article-title":"The discovery of naringenin as endolysosomal two-pore channel inhibitor and its emerging role in SARS-CoV-2 infection","volume":"10","author":"D\u2019Amore","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.cellsig.2022.110559_bb0850","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2109905118","article-title":"Furin cleavage of the SARS-CoV-2 spike is modulated by O-glycosylation","volume":"118","author":"Zhang","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cellsig.2022.110559_bb0855","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3390\/cells10030503","article-title":"Assembly and cellular exit of coronaviruses: hijacking an unconventional secretory pathway from the pre-Golgi intermediate compartment via the Golgi ribbon to the extracellular space","volume":"10","author":"Saraste","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.cellsig.2022.110559_bb0860","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41569-018-0002-3","article-title":"Cysteine protease cathepsins in cardiovascular disease: from basic research to clinical trials","volume":"15","author":"Liu","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.cellsig.2022.110559_bb0865","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1515\/bc.2011.039","article-title":"Post-transcriptional regulation of human Cathepsin L expression","volume":"392","author":"Mittal","year":"2011","journal-title":"Biol. Chem."},{"key":"10.1016\/j.cellsig.2022.110559_bb0870","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107587","article-title":"Cathepsin-L selective inhibitors: a potentially promising treatment for COVID-19 patients","volume":"213","author":"Liu","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.cellsig.2022.110559_bb0875","doi-asserted-by":"crossref","first-page":"9812","DOI":"10.1128\/JVI.01012-07","article-title":"Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum\/Golgi membrane","volume":"81","author":"Frieman","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.cellsig.2022.110559_bb0880","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2147\/JIR.S267280","article-title":"Role of IFN and complements system: innate immunity in SARS-CoV-2","volume":"13","author":"Shibabaw","year":"2020","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.cellsig.2022.110559_bb0885","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.4081\/cp.2020.1271","article-title":"COVID-19: hemoglobin, iron, and hypoxia beyond inflammation. A narrative review","volume":"10","author":"Cavezzi","year":"2020","journal-title":"Clin. Pract."},{"key":"10.1016\/j.cellsig.2022.110559_bb0890","article-title":"Hypoxia: a key feature of COVID-19 launching activation of HIF-1 and cytokine storm","volume":"17","author":"Jahani","year":"2020","journal-title":"J. Inflam. (Lond., Engl.)"},{"key":"10.1016\/j.cellsig.2022.110559_bb0895","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/s41401-020-00554-8","article-title":"Hypoxia, HIF-1\u03b1, and COVID-19: from pathogenic factors to potential therapeutic targets","volume":"41","author":"Serebrovska","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.cellsig.2022.110559_bb0900","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3390\/cells9010094","article-title":"Host calcium channels and pumps in viral infections","volume":"9","author":"Chen","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.cellsig.2022.110559_bb0905","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1021\/acsptsci.0c00219","article-title":"SARS-CoV-2, hypoxia, and calcium signalling: the consequences and therapeutic options","volume":"4","author":"Danta","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.cellsig.2022.110559_bb0910","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1024\/0300-9831\/a000676","article-title":"Vitamin D can be effective on the prevention of COVID-19 complications: a narrative review on molecular aspects","volume":"92","author":"Shiravi","year":"2022","journal-title":"Int. J. Vitam. Nutr. Res."},{"key":"10.1016\/j.cellsig.2022.110559_bb0915","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1159\/000508247","article-title":"JAK inhibition as a new treatment strategy for patients with COVID-19","volume":"181","author":"Seif","year":"2020","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.cellsig.2022.110559_bb0920","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1021\/acs.jmedchem.1c00335","article-title":"Kinases as potential therapeutic targets for anti-coronaviral therapy","volume":"65","author":"Pillaiyar","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cellsig.2022.110559_bb0925","first-page":"318","article-title":"Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact","volume":"81","author":"Cantini","year":"2020","journal-title":"J. Inf. Secur."},{"key":"10.1016\/j.cellsig.2022.110559_bb0930","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106749","article-title":"Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19","volume":"86","author":"Zhang","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.cellsig.2022.110559_bb0935","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1007\/s10067-020-05073-9","article-title":"Rheumatologists\u2019 perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets","volume":"39","author":"Misra","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.cellsig.2022.110559_bb0940","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(20)30132-8","article-title":"COVID-19: combining antiviral and anti-inflammatory treatments","volume":"20","author":"Stebbing","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.cellsig.2022.110559_bb0945","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV","volume":"11","author":"Ou","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cellsig.2022.110559_bb0950","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00726-021-02991-z","article-title":"Human cell receptors: potential drug targets to combat COVID-19","volume":"53","author":"Raghav","year":"2021","journal-title":"Amino Acids"},{"key":"10.1016\/j.cellsig.2022.110559_bb0955","doi-asserted-by":"crossref","first-page":"970","DOI":"10.3389\/fmicb.2020.00970","article-title":"Could the inhibition of Endo-lysosomal two-pore channels (TPCs) by the natural flavonoid naringenin represent an option to fight SARS-CoV-2 infection?","volume":"11","author":"Filippini","year":"2020","journal-title":"Front. Microbiol."}],"container-title":["Cellular Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656822003217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656822003217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:08:09Z","timestamp":1760267289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0898656822003217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":182,"alternative-id":["S0898656822003217"],"URL":"https:\/\/doi.org\/10.1016\/j.cellsig.2022.110559","relation":{},"ISSN":["0898-6568"],"issn-type":[{"type":"print","value":"0898-6568"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 signalome: Potential therapeutic interventions","name":"articletitle","label":"Article Title"},{"value":"Cellular Signalling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellsig.2022.110559","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110559"}}